GSK, CureVac Expand Licensing Agreement
By Anthony O. Goriainoff
GSK said that under a new licensing deal with biotech company CureVac it will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or mRNA, candidate vaccines for influenza and Covid-19.
U.K. pharmaceutical company GSK said the restructured collaboration allows both companies to prioritize their investments and focus their respective mRNA development activities.
mRNA vaccines are those which use messenger ribonucleic acid instead of an actual bacteria or virus in the production process, and were widely used to combat Covid-19.
CureVac will get a 400 million euros ($429.9 million) upfront payment and is eligible to up to a further EUR1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties in the high to low teens million range. It will also retain exclusive rights to the additional undisclosed and preclinically validated infectious disease targets from the prior collaboration.
GSK said that all financial considerations stemming from their prior collaboration deal were replaced by the new licensing agreement. It added that the new agreement's completion remained subject to some antitrust and regulatory approvals as well as the customary closing conditions.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
July 03, 2024 02:50 ET (06:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now